First AD

Second AD

Amer Zeidan, MBBS, is director of Early Therapeutics Research, director of the Leukemia and Myeloid Malignancies Program, assistant medical director of the Clinical Trials Office, and co-leader of the Leukemia and Myeloid Malignancies Clinical Research Team at Yale Cancer Center; as well as chief of the Division of Hematologic Malignancies and a professor of internal medicine (hematology) at Yale School of Medicine

Presented by Dr. Amer Zeidan, this OncLive Rapid Readout highlights results from the phase 2 ASCERTAIN-V trial, in which an all-oral regimen of decitabine-cedazuridine plus venetoclax achieved a 46.5% complete response rate and a median overall survival of 15.5 months in newly diagnosed patients with AML ineligible for intensive chemotherapy.

6504 An all-oral regimen of      decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients with      newly diagnosed AML ineligible for intensive induction chemotherapy:      Results from a phase 2 cohort of 101 pts.

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Presented by Amer Zeidan, MBBS, this OncLive Rapid Readout highlights results from the phase 2 ASCERTAIN-V trial, in which an all-oral regimen of decitabine-cedazuridine plus venetoclax achieved a 46.5% complete response rate and a median overall survival of 15.5 months in newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

An All-Oral Regimen of Decitabine-Cedazuridine (DEC-C) Plus Venetoclax (VEN) in Patients With Newly Diagnosed AML Ineligible for Intensive Induction Chemotherapy: Results From a Phase 2 Cohort of 101 Patients